Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothel...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

BG_BULL Aug. 4 at 12:39 PM

$ACHV LifeSci Capital initiated Achieve Life Sciences (ACHV) coverage with Outperform and target $17 Nice! 😎

0 · Reply

bobtheknob Aug. 1 at 12:53 AM

$ACHV I started a position in Achieve 7 years ago, my first buy adjusted for splits was $49.99. Would be nice if we land a buyout around that price, would have to be multiple bidders and very bullish scenario.

1 · Reply

ExploringTrades Jul. 28 at 10:21 PM

Ticker APUS is the next micro float squeeze ! Every micro cap ticker has been running almost 700% lately! Would not be surprised one bit if they send APUS up today . APUS starting to make its move now! Only 400k shares outstanding! 💎 Watch $SPCX $IREN $NBIS $ACHV BOOOOM

0 · Reply

Mugshot Jul. 25 at 1:22 PM

$ACHV 20%short float We are ready for a short squeeze

1 · Reply

dwilkos Jul. 24 at 9:07 PM

$ACHV https://www.wired.com/story/made-in-china-chinas-vape-makers-have-a-new-way-around-flavor-bans/

1 · Reply

Amb8675309 Jul. 22 at 11:44 PM

$ACHV put another way: a smoker who wants to quit has a 68% chance of still going back to smoking after trying cytisinicline. Relative to successful cold turkey quit rates of 5-12% and over 7-8 attempts before quitting successfully , I guess 32% is a win???? And this 32% quit rate is for smokers who also received counseling on breaking this bad habit… still not encouraging IMO, but… the VRNA crew is here now and they’re experts at marketing a newly approved drug and getting it sold… so for these reasons( leadership expertise, hype around smoking cessation, likely M&A target), it’s worth trading/investing in this name.

5 · Reply

Amb8675309 Jul. 22 at 11:37 PM

$ACHV obviously we will play the Q4/26 resubmission, but long term, a top quit rate of 32% isn’t impressing me. Looks like big tobacco won’t be going out of business anytime soon. Imagine if a new drug for cancer had only a 32% survival rate? 😂 That being said, any new cessation drug will get acquired- for a real nicotine free world, we need an 80% quit rate…. Still, share price should go up by next year….

3 · Reply

Arawn Jul. 21 at 9:47 AM

$ACHV assuming everything goes according to plan here, what are the expectations than?

4 · Reply

OnlyFibs Jul. 19 at 12:50 AM

$ACHV is consolidating after the recent volatility surrounding the FDA’s CRL. While the decision created a near-term hurdle, the technicals remain resilient with the stock holding key moving averages. Watching for volume to confirm if this base can hold as the company advances its manufacturing partnership with Adare Pharma. 🐂🎯 Bull Key Levels: A firm break and hold above $6.40 is essential to invalidate the recent downtrend and target the $7.11 yearly highs. 🐂🔥 Bear Key Levels: Defending the $6.02 support floor is critical to maintain the current structure and prevent a retest of lower support zones. 🐻⚠️ Take Profit Targets: $7.00 / $8.50. 💰💸 #hovdid #achv #biotech #stocks #trading #optionsflow

0 · Reply

bobtheknob Jul. 15 at 11:55 PM

$ACHV About 3 weeks till Q2 Report.

0 · Reply

Achieve Life Sciences initiated with an Outperform at LifeSci Capital

Aug 3, 2026, 8:30 AM EDT - 1 day ago

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

Jul 31, 2026, 8:30 AM EDT - 4 days ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Jul 2, 2026, 12:00 PM EDT - 4 weeks ago

Achieve Life Sciences Transcript: AGM 2026

2026-06-29T13:00:47.000Z - 5 weeks ago

Achieve Life Sciences added to Russell 2000 Index

Jun 29, 2026, 8:30 AM EDT - 5 weeks ago

Achieve Life Sciences Joins Russell 2000® Index

2026-06-26T12:15:27.000Z - 5 weeks ago

Achieve Life Sciences resumed with a Strong Buy at Raymond James

2026-06-22T13:45:06.000Z - 6 weeks ago

Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility

Jun 22, 2026, 8:54 AM EDT - 6 weeks ago

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug

Jun 22, 2026, 8:30 AM EDT - 6 weeks ago

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Achieve Life Sciences Proxy statement: Proxy filing

Jun 2, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

May 29, 2026, 8:00 AM EDT - 2 months ago

Achieve Life Sciences Proxy statement: Proxy filing

May 19, 2026, 2:15 PM EDT - 2 months ago

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

2026-05-12T21:31:08.000Z - 2 months ago

Achieve Life Sciences files prospectus for resale of shares by holders

May 12, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Achieve Life Sciences Registration statement: Registration filing

2026-05-12T11:58:27.000Z - 3 months ago

Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)

May 12, 2026, 7:05 AM EDT - 3 months ago

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

May 12, 2026, 7:00 AM EDT - 3 months ago

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

May 1, 2026, 7:00 AM EDT - 3 months ago

Achieve Life Sciences Slides: Corporate presentation

2026-04-21T09:20:14.000Z - 3 months ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-20T20:46:40.000Z - 3 months ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-16T15:25:18.000Z - 3 months ago

Achieve Life Sciences announces $354M private placement

2026-04-16T14:03:48.000Z - 3 months ago

Achieve Life Sciences appoints Goldberg as CEO, names two leaders to board

Apr 16, 2026, 8:57 AM EDT - 3 months ago

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Apr 16, 2026, 8:53 AM EDT - 3 months ago

Achieve Life Sciences Announces Up to $354 Million Private Placement

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Mar 26, 2026, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Mar 24, 2026, 2:23 PM EDT - 4 months ago

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Annual report: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Earnings release: Q4 2025

2026-03-24T11:10:44.000Z - 4 months ago

Achieve Life Sciences reports Q4 EPS (28c), consensus (28c)

Mar 24, 2026, 7:00 AM EDT - 4 months ago

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

2026-03-09T20:45:55.000Z - 5 months ago

Aeon Biopharma appoints John Bencich as CFO

AEON

2026-03-04T13:21:27.000Z - 5 months ago

Achieve Life Sciences announces new data on cytisinicline to be presented

Mar 4, 2026, 8:00 AM EST - 5 months ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

2026-02-06T16:15:23.000Z - 6 months ago

H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

PFE

2026-01-23T21:10:26.000Z - 6 months ago

Achieve Life Sciences files $300M mixed securities shelf

Jan 23, 2026, 7:00 AM EST - 6 months ago

Achieve Life Sciences Registration statement: Registration Filing

2026-01-12T13:55:17.000Z - 7 months ago

Achieve Life Sciences confirms promotion of Mark Rubinstein to CMO

Jan 12, 2026, 8:47 AM EST - 7 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Jan 12, 2026, 7:00 AM EST - 7 months ago

Achieve Life Sciences Slides: Corporate presentation

Dec 17, 2025, 4:11 PM EST - 8 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Nov 6, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 5, 2025, 7:00 AM EST - 9 months ago

Achieve Life Sciences Slides: Corporate Presentation

Nov 3, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 17, 2025, 7:30 AM EDT - 10 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 10 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 11 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 8, 2025, 11:00 AM EDT - 11 months ago

Achieve Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Aug 6, 2025, 6:00 PM EDT - 1 year ago

Achieve Life Sciences Slides: Corporate Presentation

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Slides: Corporate Presentation

Jun 30, 2025, 7:52 PM EDT - 1 year ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 1 year ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 1 year ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 1 year ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Achieve Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Proxy statement: Proxy Filing

Apr 21, 2025, 11:19 AM EDT - 1 year ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 12, 2025, 11:30 AM EDT - 1 year ago

Achieve Life Sciences Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Achieve Life Sciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

BG_BULL Aug. 4 at 12:39 PM

$ACHV LifeSci Capital initiated Achieve Life Sciences (ACHV) coverage with Outperform and target $17 Nice! 😎

0 · Reply

bobtheknob Aug. 1 at 12:53 AM

1 · Reply

ExploringTrades Jul. 28 at 10:21 PM

0 · Reply

Mugshot Jul. 25 at 1:22 PM

$ACHV 20%short float We are ready for a short squeeze

1 · Reply

dwilkos Jul. 24 at 9:07 PM

$ACHV https://www.wired.com/story/made-in-china-chinas-vape-makers-have-a-new-way-around-flavor-bans/

1 · Reply

Amb8675309 Jul. 22 at 11:44 PM

5 · Reply

Amb8675309 Jul. 22 at 11:37 PM

3 · Reply

Arawn Jul. 21 at 9:47 AM

$ACHV assuming everything goes according to plan here, what are the expectations than?

4 · Reply

OnlyFibs Jul. 19 at 12:50 AM

0 · Reply

bobtheknob Jul. 15 at 11:55 PM

$ACHV About 3 weeks till Q2 Report.

0 · Reply

Trigga_tha_Gambler Jul. 13 at 3:37 PM

$ACHV Lol. All sales are at a loss at these levels.

1 · Reply

CDCcsd Jul. 10 at 3:32 PM

$ACHV They've loaded the gun, they haven't fired it. Secondary at higher prices and or a buy out. This name is the closest thing to a no brainer I see in the market, buy the dips.

0 · Reply

TLC623 Jul. 10 at 1:42 PM

$ACHV Does anyone know the result of the vote on doubling the share count from 150 million to 300?

2 · Reply

V106GuY Jul. 8 at 4:01 PM

$ACHV Today's stellar performance brought to you by The Strait of Hormuz. The markets scared for now

1 · Reply

V106GuY Jul. 7 at 5:14 PM

$ACHV holding strong in a down market day. Something is brewing for a push

1 · Reply

AnomalyDetective Jul. 5 at 12:55 PM

Professor Grant's bonus Bounce-Lag breakout picks are up +164% in average cumulative returns YTD with four picks breaking 10% gains last week in the short trading week. 💥 Peak gains last week in $MRNA +21.0%, $PANW +17.7%, $GH +15.7% 💥 All new picks for Week 28 have been released to members along with new MDA Breakout picks led by $ACHV +24.7% $AARD +18.4% peak gains last week. 👉 https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6313269-bonus-bounce-lag-momentum-stocks-for-july-week-28-of-2026

0 · Reply

VCV86 Jul. 2 at 2:59 PM

$UNCY $CING $ACHV if you like post-CMC CRL setups, $GRCE looks like a great opportunity here. The stock has been hammered, and FDA alignment after the Type A meeting could come anytime.

3 · Reply

Ghostrider2020 Jul. 2 at 12:36 PM

$ACHV does anyone know when or if the shares will be margin eligible?

2 · Reply

Mugshot Jul. 1 at 7:36 PM

$ACHV healthy pull back

1 · Reply

V106GuY Jul. 1 at 6:58 PM

$ACHV that's a nice dip..

0 · Reply

Sds3n Jul. 1 at 3:33 PM

$ACHV This is potential candidate for M&A, price target could be around $15

1 · Reply

Greyhound_ Jul. 1 at 2:14 PM

$ACHV We finally have a competent CEO and management team. I personally liked Bencich, I thought he was more transparent than most -- almost to a fault - but I never understood the need for the Sopharma facility as it seemed like a massive risk particularly when Trump was elected. Look at $UNCY -- received a CRL yesterday because its CEO stuck with an Indian facility that was previously deemed to have manufacturing deficits. The FDA didn't even bother to inspect the facility in India again before issuing a blind-side rejection -- clearly their move should have been to move operations to the USA, like Achieve's CEO did. I don't love the probability of a zero-bid contract to Adare based on BoD connections, but that's the business world we operate in today where nobody bats an eye. As long as the FDA is okay with Adare, I am fine if the contract is a bit less advantageous to us than it could have been with an open RFP campaign for a new manufacturer.

2 · Reply

Market Cap	659.07M
Revenue (ttm)	0.00
Net Income (ttm)	-54.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.53

Volume	914,000
Avg Vol	1,901,594
Day's Range	N/A - N/A
Shares Out	102.66M
Stochastic %K	57%
Beta	2.21
Analysts	Strong Sell
Price Target	$14.33